Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
1. Unmet Clinical needs
(1) Drug resistance of bacteria caused by abuse of antibiotics has become one of the most urgent public health problems today, especially the most difficult to treat multi drug resistant bacteria, including MRSA, MRSE, PRSP, VRE and multidrug resistant gram-negative bacteria.
(2) Linezolid, vancomycin and teicoplanin are commercially available drugs for the treatment of MRSA. By 2015, before the expiry of the patent, the global annual sales of linezolid had stabilized at $1 billion, with a peak of $1.353 billion. In 2020, the sales of linezolid exceeded ￥1.05 billion in China.
(3) The adverse reaction of linezolid was mainly bone marrow toxicity, which led to the decrease of platelets and hemorrhage. Moreover, There are some multidrug resistant bacteria with no response to linezolid.
2. Asset’s efficacy is better than linezolid, and it is a replacement product of linezolid.
3. The asset was no cross resistance to linezolid.
(1) In vitro, Asset showed stronger antibacterial activity against a variety of linezolid resistant strains, and was superior to Tedizolid.
(2) In vivo, Its antibacterial effect on MRSA, ARE and LRSA induced systemic infections in mice was 2-4 times better than that of linezolid.
(3) In vivo, Its antibacterial effect on lethal bacteria induced pulmonary infection, MRSA induced complex/non-complex subcutaneous infections in mice is significantly better than that of linezolid.
4. Asset’s pharmacokinetic characteristics are better than linezolid, and it can achieve a low dose of 200mg, administered once a day.
5. The asset is much safety than linezolid and tedizolid.
(1) High and low dose asset have no obvious changes in blood and biochemical test in rat 35 days repeat-dose toxicity experiment. However, linezolid and tedizolid showed severe toxicity.
(2) Low dose asset does not cause myelosuppression like linezolid and tedizolid. And high dose asset’s myelosuppression toxicity is far less than linezolid and tedizolid.
(3) In male rat: NOAEL=90 mpk, Treatment window=15-18 times;In female rat: NOAEL =30 mpk, Treatment window=5-6 times.
1. Asset type: Oxazolidone antibiosis
2. Indication: bacterial infections caused by specific microbial sensitive strains, such as complex or non-complex skin and skin soft tissue infections, community/hospital acquired pneumonia, vancomycin-resistant enterococcal infections, other bone and joint infections, osteomyelitis, etc.
3. Modality: Small molecular
4. Research phase: IND
5. Cooperation demands: License-out or co-development the global right
6. Research progress:
The asset has been approved pre-IND.
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
To enable antibody characterization methodsACROBiosystems has developed a series of enzymes.such as ldeS, SpeB, EndoH, and Endo S proteases, toassist with the characterization of antibodies and theirrelated post-translational modifications (PTMs)
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
This web search service is supported by Google Inc.
A-Z
